Combination therapy with mexiletine and quinidine has been shown to be more effective than either agent alone. The ability of mexiletine monotherapy, quinidine monotherapy and mexiletine-quinidine combination therapy to suppress inducible sustained ventricular tachycardia was related to drug-induced changes in ventricular refractoriness, conduction times and monophasic action potential duration recorded from both ventricles. Ventricular tachycardia could no longer be induced in 7 (35%) of the 20 patients studied with combination therapy. This was a significantly higher proportion of patients than that of the groups responding to either monotherapy (quinidine, 10%; mexiletine, 5%).
Combination therapy with mexiletine and quinidine has been shown to be more effective than either agent alone. The ability of mexiletine monotherapy, quinidine monotherapy and mexiletine-quinidine combination therapy to suppress inducible sustained ventricular tachycardia was related to drug-induced changes in ventricular refractoriness, conduction times and monophasic action potential duration recorded from both ventricles. Ventricular tachycardia could no longer be induced in 7 (35%) of the 20 patients studied with combination therapy. This was a significantly higher proportion of patients than that of the groups responding to either monotherapy (quinidine, 10%; mexiletine, 5%).
Ventricular effective and functional refractory periods were measured when applying single (8 2 ) , double (8.1) and triple (S4) extrastimuli. Quinidine monotherapy increased functional and effective refractory periods of both single and multiple extrastimuli. However, when comparing measurements made during mexiletine treatment with those at baseline, mexiletine monotherapy increased only the refractory periods of S4' The effective Combination therapy with mexiletine and quinidine has been shown to be more effective than therapy with either agent alone for the suppression of spontaneous ventricular tachycardia (1,2). The combination of a class Ia and class Ib antiarrhythmic agent has also been reported (3) to suppress inducible sustained ventricular tachycardia. The electrophysiologic correlates of this interaction have not been sys-refractory period of 8 4 during mexiletine monotherapy (200 ± 20 ms) was significantly longer than at baseline (160 ± 21 ms). Similarly, when comparing measurements made during combination therapy with those during quinidine monotherapy, combination therapy significantly increased the refractory periods only of multiple extrastimuli. The effective refractory period of 8 4 during combination therapy (253 ± 26 ms) was significantly longer than that of quinidine monotherapy (223 ± 27 ms). The only other significant difference between combination therapy and monotherapy with either agent was a greater prolongation of conduction time to the left ventricular dyskinetic zone with combination therapy.
Therefore, mexiletine-quinidine combination therapy is associated with additional prolongation of the refractory periods of multiple extrastimuli and with further prolongation of conduction into the dyskinetic zone of the left ventricle. These electrophysiologic effects may be markers of enhanced antiarrhythmic activity.
(1 Am Coil Cardiol 1987; 10:1149-56) tematically evaluated in humans. Accordingly, we assessed the relative antiarrhythmic efficacy of mexiletine, quinidine and their combination in the suppression of inducible. sustained ventricular tachycardia. Antiarrhythmic activity was related to drug-induced changes in ventricular refractoriness, conduction times and monophasic action potential durations recorded from the right ventricle and from an area of the left ventricle with a segmental wall motion abnormality.
Methods
Study patients. Patients referred for treatment of symptomatic ventricular tachycardia or syncope of obscure origin were potential candidates for this study. After withdrawal of all antiarrhythmic medications for at least 4 half-lives. a trans venous catheter eIectrophysiologic study was performed. If sustained unimorphic ventricular tachycardia was MEXILETINE-QUINIDINE COMBINATION lACC Vol. 10. No.5 November 1987 :1149 induced, the patient remained a candidate for this study. Serial electrophysiologic testing with intravenous quinidine, disopyrarnide, procainamide and propranolol was performed unless treatment with one or more of these agents was contraindicated. When these agents were ineffective, the final criterion for entry into this study was met. All patients gave written informed consent, and this protocol was approved by the local Institutional Review Board.
Of the 20 patients admitted to this study, 19 had atherosclerotic heart disease and I had arrhythmogenic right ventricular dysplasia (Table I) . Seventeen patients presented with documentedsymptomatic ventriculartachyarrhythmias (ventricular tachycardia in 15; ventricular fibrillation in 2) and 3 had syncope of obscure origin with induciblesustained monomorphic ventricular tachycardia. Sustained unimorphic ventricular tachycardia was induced in the two individuals who had presented with ventricular fibrillation during out-of-hospital cardiac arrest. There were 15 men and 5 women, with a mean age of 54 ± 13 years. Their global left ventricular ejection fraction, assessed by nuclear angiography, was 35 ± 13%.
Study design. Oral therapy with mexiletine, quinidine or their combination was instituted in a randomized sequence. For each drug, the dose was gradually increased to the maximum well tolerated level. The dose of each agent tested in combination was the same as that of each drug tested as monotherapy. When a treatmentregimen prevented induction of ventricular tachycardia, that patient's participation was terminated and the remaining therapies were not evaluated.
Left ventricular function. Global left ventricular function and the presence of a segmental left ventricular wall motion abnormality were documented by angiography. Global left ventricular function was also assessed by radionuclide angiography during an antiarrhythmic drug-free state, and was followed serially during therapy with each agent alone and in combination.
Electrophysiologic studies. Programmed electrical stimulation techniques in this study involved the introduction of up to three right ventricular extrastimuli (10 times late-diastolic pacing threshold; 2 ms pulse width) during ventricular pacing at cycle lengths of 600, 500 and 400 ms. SI, Sz, S3 and S4 represent the stimulus artifacts of the last beat of the ventricular drive train, the first extrastimulus, the second extrastimulus and the third extrastimulus, respectively. Corresponding ventricular electrograms were designated VI. v.. V 3 and V 4. The ventricular effective refractoryperiod of the firstextrastimulus(Sz) was the longest S,Sz interval at which Sz failed to capture. The ventricular functional refractory period of the first extrastimulus (Sz) was the minimal V,Vz coupling interval during determination of the ventricular refractory curve. After determination of the ventricular effective and functional refractory periods of Sz; the first extrastimulus was introduced 10 The second extrastimulus (S,) was then introduced, and its coupling interval (S2S,) was progressively shortened. After the determination of ventricular effective and functional refractory periods of So, the second extrastimulus (SI) was placed 10 ms above the ventricular effective refractory period of S3' and the third extrastimulus (S-1) was then introduced and its coupling interval (S3S-l) progressively shortened until failure to capture. When sustained ventricular tachycardia was not induced with ventricular cxtrastimulation, ventricular burst pacing (4 and 12 stimuli) at cycle lengths from 300 to 240 ms in steps of 10 ms was applied. Sustained ventricular tachycardia \\'a.\' defined as a nonstimulated ventricular rhythm with a cycle length of less than 500 ms that lasted 30 seconds or produced hemodynamic compromise requiring immediate termination by transthoracic cardioversion or ventricular pacing. A complete antiarrhythmic response was defined as failure of the induction protocol to produce five or more nonstimulated consecutive ventricular depolarizations. A partial antiarrhythmic response was defined as the induction of ventricular tachycardia with three extrustimuli when only one or two extrastimuli had been sufficient to induced sustained ventricular tachycardia at baseline.
The follo wing electrophvsiologic variables lI 'e/"{' recorded at baseline and during drug treatments: PRoQRS. QT and RR intervals. The rate-corrected QT (QTc) interval was calculated from the formula: QTc = QT\/RR . If ventricular tachycardia was inducible, its cycle length was measured.
Monophasic action potential recordings. Ventricular monophasic action potential recordings were obtained using bipolar endocardial suction electrode techniques developed by Olsson et al. (4) . Simultaneous recordings were obtained from the right interventricular septum and from the previously defined area of wall motion abnormality in the left ventricle. The catheters were positioned until monophasic signals were noted without suction, and then suction ( -25 mrn Hg) was applied for no more than 3 minutes. The monophasic action potential signals were amplified with a direct current coupled Electronics for Medicine differential amplifier (model PHD) and recorded on an Electronics for Medicine VR-16 recorder with a frequency response to 2 kHz and paper speeds of 100 and 150 mm/s. The monophasic action potential duration was measured at 90Ck repolarization during ventricular pacing cycle lengths of 600. 500 and 400 ms. During continuous pacing, the time interval between the right ventricular apical electrogram and the upstroke of local monophasic action potent ial recordings was taken to represent intraventricular conduction time (Fig.  I ) . Both of these measurements represent the average of at least three determinations obtained after 30 consecutive pacing cycles.
Serum drug concentrations. Steady state trough serum samples were obtained at the maximal tolerated dosage of each agent and their combination. Mexiletine was assayed using high performance liquid chromatography (5.6), and quinidine was assayed using an enzymatic immunoassay (EMIT) (7) .
Patient follow-up. When induction of ventricular tachycardia was prevented by either single or combined therapy. patients were discharged and were evaluated monthly for 3 months. then every 3 months for the remainder of the fi rst year and every 6 months thereafter. Each visit included a 24 hour ambulatory electrocardiographic (ECG) recording, a 12 lead ECG. trough serum drug levels and a clinical evaluation.
Statistical analysis. Continuous data are presented as mean ± standard deviation. Analysis of variance and Duncan' s multiple range test were used to compare the effects of mcxiletine. quinidine and their combination. The proportions of patients responding to rnexiletine, quin idine and their combination were compared by Fisher's exact test.
Results
Drug treatments. The daily dose of mexiletine and quinidine monotherapy was 7 10 ::!: 160 and 1,080 ::!: .no mg. respectively. The same doses were assessed during combination therapy. Monotherapy trough serum levels were 10 ± 4 JLmollliter for quinidine and 0.7 ± 0.3 Jlg/ml for mexiletine. Combination therapy did not significantly alter quinidine (8 ± 3 JLmolJliter) or mexiletine (0.6 ± 0.3 JLg/ml) levels relative to that seen during the respective monotherapy. We have previously shown in vitro that combination of these two drugs in plasma does not alter the individual free fractions (8) . Similarly global ejection fraction was assessed during monotherapy and combination therapy, and no significant changes in ejection fraction were found. The mean ejection fraction was 35 ± 13% at baseline, 35 ± 15% during quinidine monotherapy, 30 ± 15% during mexiletine monotherapy and 30 ± 14% during combination therapy.
Ventricular tachycardia (Fig. 2) . Two patients who responded to quinidine monotherapy and one patient who responded to mexiletine monotherapy were not tested on the alternative therapies. One patient did not receive mexiletine therapy, having already responded to combination therapy. One additional patient was not tested with combination therapy because of development of dysphoric side effects resulting in withdrawal of consent. The proportion of patients whose ventricular tachycardia was no longer inducible with combination therapy (35%) was significantly greater (X 2 ; p < 0.01) than the proportion responding to either mexiletine alone (5%) or quinidine alone (10%).
Other electrophysiologic effects. Mexiletine monotherapy had no significant effect on electrophysiologic intervals during sinus rhythm. Quinidine monotherapy significantly prolonged the QTc interval from 450 ± 32 ms at baseline to 507 ± 41 ms, and significantly prolonged QRS duration from 121 ± 34 ms at baseline to 130 ± 38 ms. The effects of combined mexiletine-quinidine therapy on electrocardiographic intervals were not significantly different from those of quinidine monotherapy with one exception. The QTc interval during combination therapy (480 ± 42 ms) was significantly shorter than that during quinidine monotherapy and was not significantly different from baseline.
Ventricular refractory periods ( Table 2 ). The single extrastimulus functional and effective refractory periods were prolonged to a nearly identical extent by quinidine monotherapy and combination therapy at each of the basic drive cycle lengths examined. Although mexiletine did not prolong the single extrastimulus ventricular refractory periods, as the number of applied extrastimuli was increased, it did prolong the effective refractory period over baseline values (200 ± 20 ms for S4 with mexiletine and 160 ± 21 ms for S4at baseline, mean ± SD) (p < 0.05). Similarly, although combination therapy did not prolong the single extrastimulus ventricular effective refractory period over that seen with quinidine monotherapy (Fig. 3) , as the number of extrastimuli was increased, combination therapy significantly prolonged this period to a greater extent than did either monotherapy. During combination therapy, the ventricular effective refractory period of S3 measured at a pacing cycle length of 400 ms (228 ± 40 ms) was significantly greater than that with either monotherapy. This increase in the ventricular effective refractory period of S3 with combination treatment cannot be explained by differences in the S, S2 coupling intervals because the ventricular effective refractory period of S2 with quinidine was 258 ± 23 ms and with combination therapy it was 255 ± 28 ms. These S,S2 coupling intervals are virtually identical. Similarly, the ventricular effective refractory period of S4 measured at a cycle length of 500 ms (253 ± 26 ms) during combination treatment was significantlygreater than with either monotherapy; this increase seen with combination therapy cannot be explained by changes in the S,S2 or S2S3 coupling intervals. The ventricular effective refractory period of S,S2 was 267 ± 28 ms for quinidine and 264 ± 27 ms for combination therapy; furthermore, that of S3 was 228 ± 39 ms for quinidine and 233 ± 36 ms for combination therapy. Therefore, the coupling intervals S,S2 and S2S3 with quinidine and combination therapy were virtually identical. A similar pattern was observed for the functional ventricular refractory period. These differences between baseline and mexiletine monotherapy and between quinidine monotherapy and combination therapy were only apparent with the closely coupled stimuli achieved by using multiple extrastimuli.
Monophasic action potentials. Eleven patients consented to the additional procedures required for recording of monophasic action potentials. Three of these patients responded to a monotherapy and, therefore, recordings were not obtained for the alternative monotherapy or for com- (Table 3) were analyzed by one-way analysis of variance. Combination therapy produced a significantly greater prolongation of conduction time from the right ventricular apex to the left ventricular dyskinetic zone compared with that seen with either monotherapy ( Table 2) . A more conservative analysis (two-way analysis of variance) of the data obtained from the five patients studied during all three therapies showed the same significant difference. By the latter analysis, in these five patients, conduction time to the left ventricular dyskinetic zone during combination therapy was 156 ± 44 ms, during quinidine monotherapy it was 130 ± 30 ms and during mexiletine monotherapy it was 94 ± 13 ms (p < 0.02).
' ----: -: --------: : f ---------
Patient follow-up. Six patients were discharged while receiving combination therapy. During a mean follow-up period of 14 ± 8 months, one patient had a nonarrhythmic cardiac death. All other patients continue receiving therapy and are free of episodes of ventricular tachycardia (as assessed by serial 24 hour ambulatory ECG monitoring). Three patients who responded to single therapy are well and arrhythmia-free during follow-up. Of the 10 patients not responding to mexiletine, quinidine or the combination, ef-MEXILETINE-QUINIDINE COMBINATION *Combination therapy significantly different from either monotherapy; significant differences of other comparisons are indicated in the text. Intraventricular conduction time (CT to LV). monophasic action potential duration at 90% repolarization from the right ventricle (RV mAPD) and left ventricular dyskinetic zone (LV mAPD) and standard surface electrocardiographic intervals compared at baseline. during quinidine monotherapy. during mexiletine monotherapy and during combined therapy. All values arc in ms.
fective antiarrhythmic therapy was found for only I patient (who responded to sotalol). Of the remaining nine patients, one was discharged while receiving disopyramide (the best partially effective agent) and the other eight were given empiric amiodarone treatment.
Discussion
Enhanced antiarrhythmic efficacy has been reported (1,3) during combination treatment with mexiletine and quinidine in patients with malignant ventricular arrhythmias. In a reperfusion injury model (9) , we have shown that mexiletine and quinidine produce synergistic prolongation of ventricular refractoriness and conduction time in the infarct zone in a conscious dog model, and that these electrophysiologic changes were paralleled by enhanced antiarrhythmic efficacy. The present study confirms that synergistic antiarrhythmic and electrophysiologic changes occur with this drug combination in humans. The changes in ventricular conduction time and refractoriness observed in these studies are in keeping with the hypothesis that the synergistic effects of this combination therapy are related to an interaction affecting sodium conductance.
Synergistic effects of quinidine and mexiIetine. Hondeghem and Katzung (10) , using a computer model of the sodium channel, predicted that the combination of lidocaine and quinidine would synergistically affect extrastimulus electrophysiology. The hypothesis developed to explain these synergistic actions was based on antiarrhythmic drugs having distinctive, state-dependent dissociation and association rate constants to the sodium channel. Quinidine binds to the activated state of the sodium channel, generating a modulated activated state. The binding of quinidine to the inactivated state of the sodium channel is minimal but, if bound, recovery from inactivation is markedly prolonged (II). In contrast, lidocaine and mexiletine bind preferentially to the inactivated state of the sodium channel generating a modulated inactivated state (12, 13) . Once in the "modulated" inactivated state, quinidine can express its property to delayed recovery from inactivation (10) . Recovery from inacti vation appears to be an important determinant of ventricular refractoriness (10) . Although this is an attractive hypothesis, it has not been rigorously tested. An alternative hypothesis is that when two drugs are combined, the total number of sodium channel blocking molecules is greater than when the drugs are given as monotherapy at equal dosages.
Role of sodium channel gating in ventricular refractoriness. In the present study, the synergistic effects of combination therapy on ventricular refractoriness were most evident with the application of closely coupled extrastimuli at rapid pacing rates. The increase in the ventricular effective refractory period of S4 seen with combination therapy relative to quinidine mono therapy cannot be explained by differences in the coupling intervals of SI S2 or S2S" These coupling intervals were virtually identical. Nevertheless, the mean ventricular effective refractory period of S4 during combination therapy is 30 ms greater than that seen during treatment with quinidine alone. These observations suggest that combination therapy produces a frequency-dependent prolongation in ventricular refractoriness. The cellular mechanism of this frequency-dependent alteration in refractoriness is uncertain. Ventricular effective refractoriness is determined by a number of factors, including action po-tential duration and the time course of recovery from inactivation of the sodium channel. In this study, we observed no difference in action potential duration when comparing quinidine monotherapy and combination therapy, However, we cannot exclude differences in action potential duration of V~and VJ' Altematively, there is experimental support for the possibility that the recovery kinetics of the sodium channel can alter refractoriness. In the study by Hondeghem and Katzung (14) comparing the maximal rate of rise of the action potential of extrasystoles at various coupling intervals, combination therapy with lidocaine and quinidine produced a supra-additive depression of the maximal rate of rise (Vmax) of the action potential of closely coupled extrasystoles. This observation provides a link between drugrelated changes in the kinetics of sodium channel gating and the changes in refractoriness of closely coupled extrastimuli observed in the present study.
Pharmacodynamic interactions. The steady state serum concentrations of mexiletine and quinidine monotherapy were not altered by combination therapy; therefore, there is no evidence for a pharmacokinetic interaction, This observation is supported by in vitro observations (15) of synergistic electrophysiologic effects of combination therapy in a setting where pharmacokinetic interactions could not be operative, The mexiletine-quinidine interaction is, therefore, likely to be pharmacodynamic.
Limitations of study. There are several limitations of this study, Conduction time was measured as the time elapsed from the right ventricular electrogram to the upstroke of the local monophasic action potentials. Change in conduction time may reflect true changes in conduction velocity, but may also be effected by change in the route of propagation or change in latency, This may be particularly relevant for measurements made from the infarct zone. Monophasic action potential catheters have been used to measure local repolarization time in normal and infarct zones (16) . Although these measurements have been validated against rnicroelectrode recordings of action potential duration in normal myocardium (17) , this comparison has not been made in infarcted tissue, The monophasic action potential measurements made from the left ventricle were of lower amplitude than those recorded from the right ventricle and, therefore, these repolarization measurements may be less accurate,
Another potentia/limitation (~f this study is that, although we attempted to place the left ventricular monophasic action potential catheter into a zone of abnormal wall motion, we have no confirmation of the exact placement of this catheter in relation to infarct or border zones. Although the catheter was radiologically guided during the three individual studies (mexiletine, quinidine and their combination) to approximate the same position for each study, it is unlikely that monophasic action potential recordings were obtained in exactly the same positions in all three studies. These procedurallimitations exist for all similar clinical investigations employing these catheter techniques.
The number of patients participating in this study was small. Therefore, it is possible that additional significant electrophysiologicdifferences exist, but were not identified. Enrollment in this study was terminated on ethical grounds secondary to an unacceptable complication rate of arterial catheterization with the monophasic action potential catheter. These complications affected four patients and included a transient cerebral ischemic attack, possible myocardial perforation, iliac artery embolic occlusion and a femoral artery false aneurysm. Although no long-term sequelae occurred, two surgical procedures were required to correct these complications.
Conclusions. Combination therapy with mexiletine and quinidine suppressed the inducibility of ventricular tachycardia more than did either monotherapy. This enhanced antiarrhythmic effect is paralleled by prolongation of ventricular refractoriness and the conduction time to a zone of the left ventricle with a segmental wall motion abnormality, We hypothesize that the observed electrophysiologic differences between monotherapy with each drug and combination therapy are related to the enhanced antiarrhythmic activity of this combination.
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